		OMB APPROVAL
	UNITED STATES	OMB Number: 3235-0060
	SECURITIES AND EXCHANGE COMMISSION	Expires: February 28, 2013
	Washington, D.C. 20549	Estimated average burden
		hours per response.........5.68

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 ORor 15(d) of ~~The~~ the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) : September 1630, ~~2011~~2019

~~DIAMOND INFORMATION INSTITUTE, INC. (Exact name of registrant as specified in its charter)~~_______________________________

Wyoming	333-149978	22-2935867
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

Therapy Cells Inc.

1810 E. Sahara Ave, Suite 1454, Las Vegas, NV	89104
(Address of principal executive offices)	(Zip Code)

(Exact name of registrant as specified in its charter)

~~Registrant’s telephone number, including area code (702) 666-8570~~_______________________________

(Former name or former address, if changed since last report.)

Wyoming	333-149978	22-2935867
(State or Other Jurisdiction	(Commission	(I.R.S. Employer
of Incorporation)	File Number)	Identification No.)

~~Check~~917 ~~the~~Bobwhite ~~appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):~~Street

.Fruitland, ~~Written~~Idaho ~~communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)~~83619

.(Address ~~Soliciting~~of ~~material~~Principal ~~pursuant~~Executive ~~to Rule 14a-12 under the Exchange Act~~ Offices) (17Zip ~~CFR 240.14a-12~~Code)

~~. Pre-commencement communications pursuant to Rule 14d-2~~(b208) ~~under the Exchange Act (17 CFR 240.14d~~630-~~2(b))~~6678

~~. Pre-commencement communications pursuant to Rule 13e-4~~(c)Registrant’s ~~under~~telephone ~~the~~number, ~~Exchange~~including area ~~Act (17 CFR 240.13e-4(c~~code))

~~SEC 873 (03-10)~~N/A

~~Potential~~(Former ~~persons~~name ~~who~~or ~~are~~former toaddress, ~~respond~~if tochanged since ~~the~~last ~~collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.~~report)

~~Page~~Check 1the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of 2the registrant under any of the following provisions:

~~Item~~☐ ~~1.01~~Written ~~Entry~~communications ~~into~~pursuant ato ~~Material~~Rule ~~Definitive~~425 ~~Agreement~~under the Securities Act (17 CFR 230.425)

~~Acquisition~~☐ ofSoliciting ~~Therapy~~material ~~Cells~~pursuant ~~Limited~~to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

On☐ ~~August~~Pre-commencement ~~26,~~communications ~~2011,~~pursuant ~~Therapy~~to ~~Cells~~Rule ~~JV, Inc.~~ 14d-2(~~a wholly owned subsidiary of Diamond Information Institute, Inc.~~b) ~~entered~~under ~~into~~the ~~and~~Exchange ~~completed~~Act ~~a Stock Purchase Agreement with a limited number of sellers~~ (~~the~~17 ~~“Sellers”),~~CFR ~~for the purchase of 2000 shares of Class A Common Stock of Therapy Cells Limited~~240. 14d-2(b))

~~Item~~☐ ~~3.02~~Pre-commencement ~~Unregistered~~communications ~~Sales~~pursuant ofto ~~Equity~~Rule ~~Securities~~13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~The~~Securities ~~Private~~registered ~~Placement~~pursuant to Section 12(b) of the Act:

AsTitle of ~~August~~each ~~2011,~~class ~~Therapy~~Trading ~~Cells, Inc.~~ Symbol(~~f/k/a Diamond Information Institute, Inc.~~s), aName ~~Wyoming corporation (the "Company"), intends to raise $5 Million through its private placement~~ of ~~preferred~~each ~~Series~~exchange D stock being made in a transaction exempt from registration under the Securities Act of 1933, as amended (the "Act"), pursuant to Section 4(2) of the Act and Rule 506 of Regulation D promulgated under such section of the Act. The private offering commenced on orwhich ~~about~~registered ~~August~~N/A ~~2011~~N/A and is continuing. The Company's private placement seeks a maximum of $5,000,000 of total capital (including the overallotment provision) by offering up to 2,000,000 shares of preferred Series D stock at $2.50 per share. The placement is being made only to prospective investors who qualify as "accredited investors" as defined in Rule 501 of Regulation D of the Act. The capital raised in the private placement is expected to be utilized as follows: (1) $780,000 to operating expenses; (2) $450,000 to marketing; (3) $1,800,000 to pay for FDA approval, consultants, and related expenses; (4) $1,000,000 to research and development; (5) $970,000 held in a cash reserve. The Company plans to continue the private offering of the shares in the private placement until September 30, 2011, but, may extend the time of the offering in accordance with its terms.N/A

~~This~~Indicate ~~notice~~by ~~does~~check ~~not~~mark ~~constitute~~whether anthe ~~offer~~registrant tois ~~sell~~an ~~nor~~emerging growth acompany ~~solicitation~~as todefined ~~buy~~in aRule ~~security.~~405 ~~Any~~of ~~offer to sell or a solicitation to buy a security from~~ the ~~Company~~Securities isAct ~~made~~of ~~only~~1933 to(§230.405 ~~prospective~~of ~~investors~~this ~~with~~chapter) ~~whom~~or ~~the~~Rule ~~Company has a pre~~12b-~~existing~~2 ~~relationship~~of ~~and only by~~ the ~~complete~~Securities Exchange ~~Confidential~~Act ~~Private~~of ~~Placement~~1934 ~~Memorandum~~(§240.12b-2 ~~covering~~of ~~the~~this ~~Company's common stock in the private placement, including the risk factors described in the Memorandum~~chapter).

~~The~~Emerging ~~securities~~growth ~~offered~~company in the Company's private placement have not been registered under the Act or any state securities laws. No shares may be resold, assigned or otherwise transferred unless a registration statement under the Act is in effect, or the Company has received evidence satisfactory to it that such transfer does not involve a transaction requiring registration under the Act and is in compliance with the Act.☐

~~SIGNATURES~~If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

~~Pursuant~~ITEM 1.01 toENTRY ~~the~~INTO ~~requirements~~A ofDEFINITIVE ~~the~~MATERIAL ~~Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.~~AGREEMENT

	Company Name Diamond Information Institute, Inc.
Date: September 16, 2011	By:	/s/ Christopher Glover
		Name: Christopher Glover
		Title: Chief Executive Officer

ITEM 5.01 CHANGES IN CONTROL OF REGISTRANT

~~Page~~ITEM 8.01 2OTHER ~~of 2~~EVENTS

Therapy Cells Inc. (the “Company”) will be filing its annual reports up through the as filed Form 15-12 filed on March 1, 2012. The Company will file its Annual Reports for fiscal year ended December 31, 2010 and December 31, 2011. Also, the OTC requires a companyfile the past two years of annual reports and current quarterly reports as a voluntary filer in an effort to be transparent to its shareholders and to be qualified to be a trading company on that trading site.

Therapy Cells Inc. has been unsuccessful in raising the required capital to pursue the FDA approval of the growing of Tendon and Articular cartilage for autotransplantation into humans. Their rights to the patents have expired and Company is no longer pursuing cell therapy.

Consistent with their business plan of investing in new and emerging technologies, Therapy Cells Inc has acquired all of the assets of XTRA Bitcoin Inc. through merger on June 25, 2019 and appointed a new Board and Officers. As part of this merger acquisition, Therapy Cells Inc. has changed its name to XTRA Bitcoin Inc. and committed to bringing its filings current. Paul Knudson has been appointed as a Director and serves as the CEO and CFO currently. As a result of this merger, Paul Knudson beneficially owns approximately 18.64% of the Company.

The Company’s principal place of business is 917 Bobwhite Street, Fruitland, Idaho 83619.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

	THERAPY CELLS INC.

	By:	/s/ Paul Knudson
		Paul Knudson Chief Executive Officer

Date: October 2, 2019

Filing Compare · XTRA Bitcoin Inc.